What should I do if a patient misses a scheduled dose of, or experiences a gap in their long-acting injectable (LAI) treatment?

Please refer to the appropriate section of the FDA label as listed below for each medication. The label can be found by searching Drugs@FDA at the FDA website. Information is also available using the Drugs@FDA smartphone app.

  • Abilify Asimtufii (aripiprazole extended-release solution) – Refer to label section 2.3: Missed Doses
  • Abilify Maintena (aripiprazole monohydrate LAI) – Refer to label section 2.2: Dosage Adjustments for Missed Doses
  • Aristada (aripiprazole lauroxil LAI) – Refer to label section 2.2: Missed Doses
  • Invega Hafyera (paliperidone palmitate 6-mo LAI) – Refer to FDA label section 2.3: Missed Doses
  • Invega Sustenna (paliperidone palmitate LAI) – Refer to label section 2.3: Missed Doses
  • Invega Trinza (paliperidone palmitate 3-mo LAI) – Refer to label section 2.3: Missed Doses
  • Perseris (risperidone sub-cutaneous LAI) – Refer to label section 2.1: Recommended Dosage
  • Risperdal Consta (risperidone LAI) – Refer to FDA label section 2.1: Schizophrenia/Reinitiation
  • Rykindo (risperidone for extended-release solution)  – Refer to label section 2.5: Reinitiation of Treatment in Patients Previously Discontinued
  • Uzedy (risperidone for extended-release solution) – Refer to label section 2.1: Recommended Dosage

There is no specific guidance from the FDA on how to handle missed doses of the following LAIs:

  • Haldol decanoate (haloperidol LAI)
  • Prolixin decanoate (fluphenazine LAI)
If you would like more information on this topic, or would like to provide any feedback, please send us a message using our consultation system. Be sure to let us know about which tip you are writing. We would love to hear from you, and the consultation system is free to use and confidential. Thank you!
  • Was this Helpful ?
  • YesNo

Join our #MissionForBetter now

Sign up for our newsletter. We’ll let you know about new resources, education, and more.

non-image